Two children diagnosed with diffuse intrinsic pontine glioma – a brain tumor that kills most kids within a year – were still alive more than 21 and 32 months after receiving an experimental cell therapy. Their oncologists had not expected either outcome. The therapy hadn’t even been designed with survival as its primary goal.
The treatment at the center of those results is called tumor-associated antigen T cell therapy, and it works by training a patient’s own immune cells to recognize and attack proteins that are overexpressed on pediatric brain tumor cells. The findings come from a clinical trial that ran for nearly six years at one of the country’s leading pediatric research hospitals, and they have generated serious attention in a field that has seen very little good news for a very long time.
Brain tumors remain the leading cause of cancer-related deaths in children. Within that category, few diagnoses carry a grimmer prognosis than diffuse intrinsic pontine glioma, known as DIPG. DIPG is a highly aggressive brainstem tumor characterized by diffuse infiltration of the pons, rapid neurologic decline, and markedly limited long-term survival. Its location makes surgical resection unsafe, leaving radiation therapy as the primary option for temporary symptom relief. For decades, nothing has meaningfully changed that picture.
What DIPG Actually Does to Children
DIPG is an aggressive brain tumor growing inside the pons region of the brainstem, primarily affecting children aged 5 to 9. The pons controls breathing, heart rate, and swallowing, which is precisely why surgery is off the table. According to the National Cancer Institute, approximately 300 children are diagnosed with DIPG in the United States each year.
DIPG accounts for 10 to 15% of all pediatric brain tumors and is a leading cause of death in children with brain cancer. The standard treatment – radiation – buys time but offers no cure. Children who receive radiation therapy alone live for approximately 10.4 months after diagnosis, according to a 2024 registry study from the European Society for Pediatric Oncology. Adding chemotherapy pushes that figure to about 11.7 months. Survival beyond two years occurs in fewer than 10% of patients.
Those numbers have barely moved since the disease was first characterized. The immunotherapy approach tested in the ReMIND trial represents one of the more credible attempts to do something different.
The Design of the ReMIND Trial
The ReMIND trial enrolled pediatric and young adult patients with CNS malignancies from September 18, 2018 to July 18, 2024. It was a first-in-human Phase 1 clinical trial led by researchers at Children’s National Hospital in Washington, D.C.
The primary endpoints of the trial were safety and feasibility of intravenously administered TAA-T therapy and determination of the maximum tolerated dose. In other words, this was a safety study. The researchers were asking whether the treatment could be given without harming patients – not yet whether it could reliably save their lives. The fact that it did something more than that is what makes the results notable.
The trial showed that a new autologous multi-antigen T cell therapy can be delivered intravenously and reach the brain through the bloodstream to fight off brain tumors in children – a delivery method that sets it apart from other approaches in the space. Many competing experimental therapies for DIPG require the T cells to be injected directly into the brain’s ventricles. The ReMIND approach used a standard IV infusion, a meaningful practical difference if the therapy eventually moves toward broader use.
How the Brain Cancer Cell Therapy Works
The therapy targets three proteins – WT1, PRAME, and survivin – that are commonly overexpressed in pediatric brain tumors. These are called tumor-associated antigens (TAAs), meaning the proteins appear at higher levels on cancer cells than on healthy tissue. Researchers drew immune T cells from each patient, expanded and trained those cells in the lab to recognize all three proteins, then infused them back into the patient’s bloodstream.
By simultaneously targeting WT1, PRAME, and survivin, the therapy raises the bar for tumor escape. For a cancer cell to evade the treatment, it would need to lose expression of all three proteins at once, which is biologically far less likely than evading a single-target therapy.
Immunotherapies have been shown to work in blood cancers but rarely succeed in solid tumors, especially brain tumors. The brain’s unique biology is a large part of why. CAR T therapy use in brain tumors is particularly challenging due to the brain tumor microenvironment, including immune suppression, antigen heterogeneity, poor T cell trafficking, and the blood-brain barrier. The blood-brain barrier is a tightly regulated boundary that prevents most molecules – including most immune cells – from passing from the bloodstream into the brain. The fact that the intravenously delivered T cells in the ReMIND trial appear to have reached brain tumors and produced responses is, by itself, a significant finding.
What the Trial Results Showed
The T cell therapy was well tolerated with low-grade side effects across the 33 patients enrolled. None of the dosage levels reached toxicity, and there were only two severe adverse events. For a Phase 1 trial studying a novel therapy in children with aggressive brain tumors, that safety profile is an important foundation.
In the Phase 1 ReMIND trial, treatment was generally well tolerated with one complete response and three long-term responders. Those four outcomes are the headline numbers. In a disease where nearly every child dies within a year, having any patients achieve long-term survival is medically unusual.
The survival data for DIPG patients specifically tells a clearer story. Two participants in the DIPG arm experienced prolonged survivals of 32 and 21 months respectively, with the latter still alive at last follow-up. The median overall survival for DIPG patients without lymphodepletion on the ReMIND trial was 13.7 months – a figure that exceeds the historical median under standard treatment by more than two months, and one that includes patients who did not respond to the therapy at all. Among the responders, the gap is far wider.
For patients with relapsed or recurrent non-brainstem malignancies in the trial, the median progression-free survival was 5 months from infusion. Given that many of these patients had already exhausted other treatment options, sustained disease control at that level carries real clinical weight.
Catherine Bollard, MBChB, MD, senior vice president and chief research officer at Children’s National and co-senior author of the study, said: “This study represents an important step toward developing safer and more effective T-cell therapies for children with devastating brain cancers.”
The study evaluated the safety and feasibility of intravenous infusion of multi-antigen-specific T cells targeting WT1, PRAME, and survivin in children with newly diagnosed DIPG or recurrent brain tumors. The study met its primary endpoints while also producing clinical responses – including a durable complete remission – as secondary endpoints.
The findings were published in Nature Medicine.
Why Single-Target Therapies Have Struggled
To understand why the multi-antigen design matters, it helps to know what has happened with other immune cell approaches. Two early-phase clinical trials investigated delivering CAR T cells directly into the ventricles of the brain for DIPG – a method called intracerebroventricular infusion. Those trials produced early signs of response, but the genetic engineering required to create CAR T cells introduces its own complexity, cost, and manufacturing constraints.
CAR T-cell therapy has delivered unprecedented clinical benefit in blood cancers, yet its successful translation to solid tumors remains a major unmet clinical challenge. Brain tumors in particular present barriers including intratumoral heterogeneity, antigenic escape, a highly immunosuppressive tumor microenvironment, and anatomical constraints imposed by the blood-brain barrier. When a tumor loses the single surface protein a CAR T cell is designed to find, the treatment stops working. Targeting three proteins at once directly addresses that escape route.
The ReMIND approach also avoids genetic engineering entirely. The T cells used in the therapy are autologous – drawn from the patient – and non-genetically modified. That keeps the manufacturing process simpler, which matters for scalability and for the long-term question of whether this treatment can eventually reach patients beyond elite research hospitals.
What Comes After a Phase 1 Trial
Phase 1 trials are inherently limited. They enroll small numbers of patients, they’re designed to test safety rather than effectiveness, and they don’t include a control group. A small, uncontrolled safety trial can suggest promise without confirming it. The ReMIND results are genuinely encouraging, but they are a starting point, not a conclusion.
Two follow-on trials at Children’s National Hospital aim to personalize the treatment further by opening the blood-brain barrier and custom-training T cells against each patient’s unique tumor antigens – a more targeted approach that, if successful, could improve on the already notable results seen in ReMIND. The IMPACT trial (NCT06193759) is now actively recruiting at ClinicalTrials.gov and has an estimated completion date extending through 2032.
Separately, the FDA has granted breakthrough therapy designation to BCB-276, an investigational CAR T-cell therapy targeting the protein B7-H3 on DIPG cells, according to Targeted Oncology. That designation is intended to accelerate the development and review of drugs that show early evidence of meaningful benefit over existing options. The ReMIND results and the BCB-276 designation arriving in the same period reflect a broader shift in momentum in this space.
Read More: Teenage Boy Cured of Lethal Brain Cancer in World First
What This Means for Families and Physicians
A DIPG diagnosis today still carries an almost uniformly devastating prognosis. Standard radiation remains the backbone of treatment, and no therapy has yet been approved that reliably extends survival beyond a year. Families navigating this diagnosis should ask their oncologist about active clinical trials, since participation in trials like ReMIND and its successors represents the most direct route to experimental therapies with emerging evidence behind them. The National Cancer Institute maintains an updated listing of DIPG-specific trials at its DIPG patient information page.
The ReMIND trial’s most important contribution may not be the survival numbers themselves, but what they prove is possible. For years, the prevailing assumption was that brain tumors – particularly brainstem tumors – were simply not accessible to systemic immune cell therapies. The fact that intravenously administered T cells reached the tumors and produced durable responses in some patients rewrites that assumption. It tells researchers where to look next, and it gives families and clinicians a reason to believe that the next generation of brain cancer cell therapy trials will have a stronger foundation to build on.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.